Combination versus single-agent as palliative chemotherapy for gastric cancer

[1]  E. Lee,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016 , 2019, Cancer research and treatment : official journal of Korean Cancer Association.

[2]  S. Kang,et al.  The role of surgical resection before palliative chemotherapy in advanced gastric cancer , 2019, Scientific Reports.

[3]  Paula Esther Moraga-Serrano.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016:A Systematic Analysis for the Global Burden of Disease Study , 2018 .

[4]  S. Kang,et al.  The role of third-line chemotherapy in recurrent or metastatic gastric cancer , 2018, Medicine.

[5]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 , 2018, JAMA oncology.

[6]  J. E. Lee,et al.  The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer , 2018, The Korean journal of internal medicine.

[7]  B. Gloor,et al.  Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population , 2018, Gastric Cancer.

[8]  E. Baba,et al.  First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study , 2018, Gastric Cancer.

[9]  Miao Zhang,et al.  High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis , 2017, BioMed research international.

[10]  N. Syn,et al.  Chemotherapy for advanced gastric cancer. , 2017, The Cochrane database of systematic reviews.

[11]  Dai Lin,et al.  Antidiabetic Micro-/Nanoaggregates from Ge-Gen-Qin-Lian-Tang Decoction Increase Absorption of Baicalin and Cellular Antioxidant Activity In Vitro , 2017, BioMed research international.

[12]  Su Jin Lee,et al.  A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. , 2017, Journal of geriatric oncology.

[13]  Xi Zhang,et al.  An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis , 2017, Disease markers.

[14]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[15]  Xueyuan Cao,et al.  Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis , 2017, Disease markers.

[16]  Liang-Che Chang,et al.  The Ratio of Hmox1/Nrf2 mRNA Level in the Tumor Tissue Is a Predictor of Distant Metastasis in Colorectal Cancer , 2016, Disease markers.

[17]  Xinghua Gao,et al.  Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis , 2016, Disease markers.

[18]  Wei Li,et al.  Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer , 2015, Oncology letters.

[19]  M. Brock,et al.  Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  D. Sun,et al.  Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer , 2015, Gastric Cancer.

[21]  Hyunsoon Cho,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[22]  Kazuhiro Yoshida,et al.  Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START) , 2013, Journal of Cancer Research and Clinical Oncology.

[23]  Ken Kato,et al.  Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[24]  J. Lee,et al.  Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy , 2013, BMC Cancer.

[25]  Y. Hui,et al.  The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer , 2013, BMC Cancer.

[26]  K. Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010 , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[27]  N. Boku,et al.  Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer , 2013, International Journal of Clinical Oncology.

[28]  S. Lim,et al.  Comparison of Two Inflammation-Based Prognostic Scores in Patients with Unresectable Advanced Gastric Cancer , 2012, Oncology.

[29]  J. Syrios,et al.  Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  H. Imamura,et al.  Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) , 2011, Gastric Cancer.

[31]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[32]  E. Winer,et al.  Lymphopenia associated with adjuvant anthracycline/ taxane regimens. , 2008, Clinical breast cancer.

[33]  Shigemi Matsumoto,et al.  The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric Cancer , 2008, Oncology.

[34]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[35]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Haerting,et al.  Chemotherapy for advanced gastric cancer. , 2005, The Cochrane database of systematic reviews.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.